Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

BACKGROUND: In a randomised phase III trial, sunitinib significantly improved efficacy over interferon-α (IFN-α) as first-line therapy for metastatic renal cell carcinoma (mRCC). We report the final health-related quality of life (HRQoL) results. METHODS: Patients (n=750) received oral sunitinib 50 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837567/
https://www.ncbi.nlm.nih.gov/pubmed/20104222
http://dx.doi.org/10.1038/sj.bjc.6605552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837567/
https://www.ncbi.nlm.nih.gov/pubmed/20104222
http://dx.doi.org/10.1038/sj.bjc.6605552

Ejemplares similares